Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
- Resource Type
- journal article
- Source
- Journal of Clinical Oncology; 11/1/2009, Vol. 27 Issue 31, p5270-5277, 8p
- Subject
- Language
- ISSN
- 0732183X